The serum proteome of nonalcoholic fatty liver disease: A multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis
- 15 October 2014
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 29 (10), 1839-1847
- https://doi.org/10.1111/jgh.12614
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common condition affecting up to 25% of the developed world. It is a progressive disease, leading in some to the development of liver cirrhosis. Currently, accurate diagnosis and staging of this condition is only possible with histological examination of a liver biopsy. This gold standard test is neither suitable nor practical for large-scale use as is necessary for a condition as common as NAFLD. The aim of this study is to describe the proteome of human NAFLD using two distinct shotgun proteomic methods, translating the findings into potential biomarkers of NAFLD. Two distinct shotgun proteomic techniques (iTRAQ and label free) were used to describe the proteome of NAFLD. Thereafter, candidate biomarkers were selected for validation by ELISA. Over 550 protein identifications were made in the description of the NAFLD proteome. Several proteins were found to be significantly up/downregulated in nonalcoholic steatohepatitis compared with control, including apolipoprotein E (fold ratio of 1.67), insulin-like growth factor-binding protein 3 (IGFBP3, fold ratio of 1.642), Vitamin D-binding protein (fold ratio of 4.587), and lymphocyte cytosolic protein1 (LCP1, fold ratio of 4.356). ELISA validation of a subset of these proteins confirms the validity of the proteomic studies and suggests possible new biomarkers of NAFLD. Serum markers are able to distinguish between the stages of disease in NAFLD as well as detect the grade of fibrosis. Ultimately, noninvasive serum markers may replace liver biopsy in the investigation of patients with suspected NAFLD.Keywords
Funding Information
- Translational Medicine Research Collaboration
- EPSRC Grant (EP/E49370/1)
- 2007 DTI grant “New serum Biomarkers for Preclinical and Clinical Drug Safety Assessment”
This publication has 33 references indexed in Scilit:
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced diseaseGut, 2008
- Nonalcoholic Fatty Liver DiseaseAnnals of Epidemiology, 2007
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDHepatology, 2007
- Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver diseaseBMC Gastroenterology, 2006
- Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver DiseaseGastroenterology, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005
- Serum markers detect the presence of liver fibrosis: A cohort studyGastroenterology, 2004
- The epidemiology of fatty liverEuropean Journal of Gastroenterology & Hepatology, 2004
- Liver fibrosis in overweight patientsGastroenterology, 2000
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal Of Gastroenterology, 1999